This study is looking at new ways to treat non-Hodgkin lymphoma and Hodgkin lymphoma in children, adolescents, and young adults (ages 3 to 39). Researchers want to see if adding targeted immunotherapy drugs like polatuzumab vedotin or nivolumab to standard chemotherapy can be safe and help reduce the amount of anthracycline (a type of chemotherapy) needed, while still controlling the lymphoma. The study will enroll about 80 participants and will measure serious side effects related to polatuzumab vedotin and nivolumab over one year to see if these new combinations are safe. The goal is to find treatments that are effective with fewer side effects for these types of lymphoma.

Study design

This is an interventional study with an unclear phase, planning to enroll about 80 participants. It is exploring different combinations of chemotherapy and immunotherapy drugs.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for Grade 3 and 4 Adverse Events related to polatuzumab vedotin and nivolumab for one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.